Patent applications published 31 March 2010
Patent applications taken from the weekly European Patents Bulletin
- Methods and compsns to inhibit edema factor and adenylyl cyclase
Mission Pharmacal Co; Board of Regents, The University of Texas System 2166841*
- Tricyclic anilide heterocyclic CGRP receptor antagonists
Merck Sharpe & Dohme 2166842*
- Treatment of viral infections by modulation of host cell metabolic pathways
The Trustees of Princeton University 2166843*
- Reduced mass, long-acting dosage forms
Surmondics Pharmaceuticals 2166844*
- Alpha connexin C-terminal (ACT) peptides for treating age-related macular degeneration
Musc Foundation for Research Development 2166845*
- Inhibitors of janus kinases
Merck Sharp & Dohme 2166846*
- CETP inhibitors derived from benzoxazole arylamides
Merck Sharp & Dohme 2166847*
- Spiroindolines as modulators of chemokine receptors
Glaxo Group 2166848*
- Substituted pyrazole compounds
Miikana Therapeutics 2166849*
- New heterocyclic H3 antagonists
High Point Pharmaceuticals 2166850*
- Therapeutic pyrazoloquinoline derivatives
Helicon Therapeutics 2166852*
- Therapeutic pyrazolonaphthyridine derivatives
Helicon Therapeutics 2166853*
- Trizole derivatives for treating Alzheimer’s disease and related conditions
Merck Sharp & Dohme 2166854*
- Chemical compounds
GlaxoSmithKline 2166856*
- Kinase inhibitor compounds
Xcovery 2166857*
- Novel heterocyclic compounds and uses thereof
Intra-Cellular Therapies 2166858*
- Quinazoline salt compounds
SmithKline Beecham 2166859*
- Novel heterocycle compounds and uses thereof
Intra-Cellular Therapies 2166860*
- Agents comprising an anti-irritant active substance
Henkel 2167030*
- Hyperbranched polymers based on cyclodextrins and poly(amidoamines) for the controlled release of insoluble drugs
L’urederra, Fundación Para El Desarrollo Tecnológico Y Social 2167031*
- Pharmaceutical formulation comprising an insulin derivative
Novo Nordisk 2167032*
- Once daily oral dosage form comprising tacrolimus
LifeCycle Pharma 2167033*
- Film shreds and delivery systems incorporating same
MonoSol 2167034*
- Chondrocyte container and method of use
DuPuy Mitek 2167035*
- Compsns for delivering a drug
Dow Corning 2167036*
- Compsns for delivering a drug
Dow Corning 2167037*
- Use of TACI-IG fusion protein such as atacicept for the manufacture of a medicament to treat lupus erythematosus
Zymogenetics 2167038*
- Improved depot formulations
Durect Ciorp 2167039*
- Intranasal carbotecin formulations and methods for the treatment of autism
MDRNA 2167040*
- Stabilised thrombin compsns
Zymogenetics 2167041*
- Pharmaceutical aerosol compsns comprising fluticasone
Generics [UK] 2167042*
- Nutraceutical co-crystal compsns
University of South Florida 2167043*
- Mucoadhesive vesicles for drug delivery
BioCure; Hirt, Thomas; Lu, Zhihua; Meier, Wolfgang; Amji, Mansoor 2167044*
- Topical poloxamer formulations for enhancing microvascular flow; compsns and uses thereof
University of Virginia Patent Foundation 2167045*
- Pharmaceutical solid preparation comprising benzazepines and production method thereof
Otsuka Pharmaceutical 2167046*
- Process for forming solid oral dosage forms of angiotensin II receptor antagonists
Dexcel 2167047*
- A novel tablet dosage form
Wockhardt Research Centre 2167048*
- Tamper resistant lipid-based oral dosage form for opioid agonists
Shear/Kershman Laboratories 2167049*
- Taste masked pharmaceutical compsns of S-alkylisothiouronium derivatives
Meditor Pharmaceuticals 2167050*
- Biocide capsules, preparation comprising them and sanitary pad comprising the preparation
Dolhay Klinika Egészségügyi 2167052*
- Nanocapsules with liquid lipidic core loaded with water-soluble or water-dispersible ingredient(s)
Universite d’Angers 2167053*
- Method for preparing lipid nanoparticles
Universite d’Angers 2167054*
- Transdermal tobacco alkaloid reservoir patch
Fertin Pharma 2167055*
- Transdermal and transmucosal drug delivery enhancers
Sinclair Pharmaceuticals 2167056*
- PDE inhibitors for the treatment of hearing impairment
Bayer Healthcare 2167057*
- Family of PFKFR3 inhibitors with anti-neoplastic activities
University of Louisville Research Foundation 2167058*
- Novel prolactin compounds
Novo Nordisk 2167059*
- Synergistic combinations for treating hypertension
Lycored 2167060*
- Dermatological and cosmetic depigmenting compsns, methods for the preparation thereof and uses thereof
Galderma Research & Development 2167061*
- Compsns and uses comprising a retinoid compound, an anti-irritant compound and benzoyl peroxide in acne
Galderma Research & Development 2167063*
- Compsns and methods for treating obesity and related disorders
Vivus 2167064*
- Combination therapy for depression
The General Hospital Corp 2167065*
- Droxidopa and pharmaceutical compsn thereof for the treatment of mood disorders, sleep disorders or attention deficit disorders
Chelsea Therapeutics 2167066*
- Use of eflucamibe for the production for a medicament for the prevention or treatment of a disease caused by sebaceous gland dysfunction in humans or animals
Galderma Research & Development 2167067*
- Anticonvulsive pharmaceutical compsns
INSERM - Institut National de la Santé et de la Recherche Médicale 2167068*
- Cholesterol-interacting layers phyllosilicates and methods for reducing hypercholesteremia in a mammal
Amcol International 2167069*
- Use of nitric oxide releasing compounds in the treatment of chronic pain
Nicox 2167070*
- A baclofen solution for low-volume therapeutic delivery
Watne State University Board of Governors; Phase V Pharmaceuticals 2167071*
- Use of olecanthal for treatment of cutaneous inflammation
BC Developments 2167072*
- Terpenes with antifungal activity against Malassezia yeasts
Instituto Biomar 2167073*
- Antibiotic compounds
Northeastern University 2167074*
- Mixed lineage kinases and metabolic disorders
University of Massachusetts 2167075*
- Hydroxyproline compsns and uses thereof
Bergen Teknologioverforing 2167076*
- Aryl/hetarylamides as modulators of the EP2 receptor
Bayer Schering Pharma 2167077*
- Use of pactimibe for the preparation of a drug intended to prevent or treat a disease caused by a sebaceous gland dysfunction in humans or animals
Galderma Research & Development 2167078*
- Steroid-sparing methods of treating brain oedema
Neutron 2167079*
- Pharmaceutical formulation comprising pramipexole
Boehringer Ingelheim International 2167080*
- Bactericidal anti-MRSA active pharma-ceutical compsn containing carbapenems
Pfandler, Hans Rudolf 2167081*
- Compsn for the treatment of metabolic disorders
Gilead Sciences 2167082*
- Novel 1-heteroaryl-3-azabicyclo[3.1.0]hexanes, methods for their preparation and their use as medicaments
DOV Pharmaceutical 2167083*
- An allergen dosage form comprising an antihistamine
ALK-Abelló 2167084*
- 4-[2-(4-methylphenylsulphanyl)phenyl]piperidine for the treatment of irritable bowel syndrome (IBS)
H Lundbeck 2167085*
- Combination of CHL and PARP inhibitors for the treatment of cancers
AstraZeneca 2167086*
- New silver(1) compounds and their use in pharmaceutical compsns for the treatment, prophylaxis and prevention of infections
CSE Incubation 2167087*
- Therapeutic compsns and the use thereof
Gilead Sciences 2167088*
- Therapeutic compsns and the use thereof
Gilead Sciences 2167089*
- HDAC inhibitors and hormone targeted drugs for the treatment of cancer
University of Maryland 2167090*
- Cinnoline compounds for use in the treatment of schizophrenia
AstraZeneca 2167091*
- Quinazoline derivatives as P13 kinase inhibitors
GlaxoSmithKline 2167092*
- Pharmaceutical compsns for the treatment of chronic heart failure comprising pyrazolopyrimidine derivative compound
Dong-A Pharmaceutical 2167093*
- Methods for treatment and prevention of tauopathies and amyloid beta amyloidosis by modulating CRF receptor signalling
Research Development Foundation 2167094*
- Compounds for treatment
Wista Laboratories 2167095*
- Improving the tolerability of mirtazapine and a second active by using them in combination
Cypress Bioscience 2167096*
- Metal complexes incorporated within biodegradable nanoparticles and their use
The University of Akron 2167097*
- Allopregnanolone in a method for enhancing neurological function (Alzheimer’s disease)
University of Southern California, Stevens Hughes Centre 2167098*
- Treatment of pulmonary hypertension with carbonic anhydrase inhibitors in combination with a sympathomimetic amine
Vivus 2167099*
- The redox/fyn/c-cbl pathway
University of Rochester 2167100*
- Antibodies and SIRNA against growth hormone, prolactin and proliferin for use in the treatment of tumours and endometriosis
Aukland Uniservices 2167101*
- Use of hyaluronic acid for preparing compsns particularly for improving the function of skin, eye and mucous membrane protection
Agro Industrie Recherche et Developpements; INSERM (Institut National de la Santé et de la Recherche Médicale) 2167102*
- Self-assembling amphiphilic polymers as anticancer agents
Allexcel 2167103*
- Bifunctional synthetic molecules
BioChemicals 2167104*
- Antimicrobial film-forming compsn, antimicrobial film, and method of verifying the presence of an antimicrobial film
3M Innovative Properties Co 2167105*
- Stabilised ophthalmic solutions
Johnson & Johnson Vision Care; Collins, Gary; Mahadevan, Shivkumar; Molock, Frank 2167106*
- Inhibitors of NCCA-ATP channels for therapy
University of Maryland, Baltimore 2167107*
- Skin-derived precursor cells and uses thereof
The Hospital For Sick Children, Toronto 2167108*